Lyon, may 30, 2017 – 18h CET – Adocia (Euronext Paris : FR0011184241 – ADOC), a biopharmaceutical company specializing in the treatment of diabetes through innovative formulations of proteins approved, today announced that the company has been invited to make a presentation in New York at the conference 2017 Global Healthcare Jefferies that will be held from 6 to 9 June 2017 in New York City.
Download the free guide
Boost your gains
The presentation will take place on Tuesday, June 6, at 8: 30 am. It will be followed at 9 a.m., with a session appointment.
Dr. Gérard Soula, President and General Manager, and Mr. Stephen Daly, US General Manager of Adocia, will participate in individual meetings with investors, organized in the framework of the conference.
About ADOCIA
Adocia is a biotechnology company clinical stage specialized in the development of innovative formulations of proteins already approved. The portfolio of injectable products of Adocia for the treatment of diabetes, which includes four products in clinical phase and six products in the preclinical phase, is one of the widest and most differentiated in the industry.
The platform’s proprietary technology BioChaperone® aims to improve the effectiveness and/or safety of therapeutic proteins and facilitate their use by patients. Adocia customizes BioChaperone to each protein for a given application, in order to address needs specific to patients.
The clinical pipeline of Adocia includes four innovative formulations of insulin for the treatment of diabetes: two formulations, ultra-fast insulin analog (BioChaperone Lispro U100 and U200), a formulation of rapid-acting insulin human (HinsBet U100), and a combination of slow insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of glucagon, human (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1 (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with hormones prandial synergistic (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide) and a concentrated formulation is fast-acting insulin human (HinsBet U500), all in preclinical development.
Adocia aims to deliver “innovative medicines for everyone, everywhere.”
To learn more about Adocia, please visit us on www.adocia.com
Download the free guide
Boost your gains
